izalontamab brengitecan + pembrolizumab

Izalontamab brengitecan + pembrolizumab is a combination therapy comprising an innovative **antibody-drug conjugate** (izalontamab brengitecan; also known as Iza-bren) and an immune checkpoint inhibitor (**pembrolizumab**, marketed as Keytruda). **Izalontamab brengitecan** is a bispecific ADC that simultaneously targets **EGFR (epidermal growth factor receptor)** and **HER3 (human epidermal growth factor receptor 3)**, common drivers in various epithelial cancers including non-small cell lung cancer. Upon binding, the ADC exerts dual antitumor activity by blocking receptor signaling and delivering a potent cytotoxic (topoisomerase 1 inhibitor) payload directly into cancer cells, inducing DNA damage and apoptosis. **Pembrolizumab** is a humanized monoclonal antibody targeting **PD-1 (programmed cell death 1)**, blocking its interaction with PD-L1 and PD-L2 to promote antitumor immune response. Combination therapy leverages targeted cytotoxicity and immune checkpoint blockade, potentially enhancing clinical efficacy and overcoming resistance pathways in EGFR- and HER3-driven tumors, especially in previously treated EGFR-mutant NSCLC[2][5][6][8].